Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Vir Biotechnology's Days Payable or its related term are showing as below:
VIR'
s Days Payable Range Over the Past 10 Years
Min: 16.14 Med: 841.94 Max: 253470.6
Current: 253470.6
During the past 9 years, Vir Biotechnology's highest Days Payable was 253470.60. The lowest was 16.14. And the median was 841.94.
VIR's Days Payable is ranked better than 99.72% of 702
companies
in the Biotechnology industry
Industry Median: 110.69
vs VIR: 253470.60
Vir Biotechnology's Days Payable
declined
from Jun. 2025 (66,193.58) to Jun. 2026 (0.00).
It may suggest that Vir Biotechnologyaccelerated paying its suppliers.
The historical data trend for Vir Biotechnology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vir Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vir Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vir Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Vir Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vir Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vir Biotechnology (VIR) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vir Biotechnology and its competitors. Over the past decade, Vir Biotechnology's Days Payable has ranged from 16.14 to 253,470.60. According to the industry distribution chart, Vir Biotechnology ranks #2 out of 702 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Vir Biotechnology's Days Payable too high?
Vir Biotechnology's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 16.14 to a high of 253,470.60. Based on the distribution chart, Vir Biotechnology ranks #2 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vir Biotechnology has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vir Biotechnology's Days Payable compare to AVBP and XNCR?
According to the Biotechnology industry distribution chart, Vir Biotechnology ranks #2 out of 702 companies for Days Payable. This places Vir Biotechnology in the top 0% of its industry — outperforming the majority of peers. The industry median Days Payable is 110.69. Historically, Vir Biotechnology's own Days Payable has ranged from 16.14 to 253,470.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.69, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vir Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 110.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vir Biotechnology's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vir Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Vir Biotechnology (VIR) is currently considered Possible Value Trap. The stock's GF Value™ is $42.26, compared to a current price of $9.50 — trading 77.5% below its estimated fair value. The current Days Payable is 0.00. Vir Biotechnology's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vir Biotechnology (VIR), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vir Biotechnology (VIR) Overvalued in 2026?
Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued.
The current stock price of $9.50 is trading 77.5% below its estimated GF Value™ of $42.26.
GuruFocus considers Vir Biotechnology to be Possible Value Trap.
Key valuation signals for VIR:
Days Payable: 0.00
GF Value™: $42.26 vs. price of $9.50 (77.5% below fair value)
No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score
Get the complete analysis for VIR
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VIR has been successfully added to your 
